Mereo BioPharma vs Spruce Biosciences
MREO and SPRB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MREO and SPRB compare
Mereo BioPharma is the larger company, worth 2.0 times as much as Spruce Biosciences ($244M against $121M).
Spruce Biosciences scores higher on the StockData Score (3 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MREO | SPRB |
|---|---|---|
| Size and price | ||
| Market cap | $244M | $121M |
| Share price | $0.305 | $42.25 |
| Change, 1 year | −82.9% | −62.5% |
| Change, 5 years | −83.9% | −79.5% |
| Beta (5Y) | 2.15 | 0.06 |
| Employees | 39 | 8 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 10.3× | 1.5× (better) |
| FCF yield | −9.1% | – |
| Profitability | ||
| Return on equity | −76.6% (better) | −106% |
| Financial health | ||
| Debt / equity | – | 0.08 |
| Interest coverage | −440.6× | −26.6× (better) |
| Current ratio | 5.22 | 9.23 (better) |
| Altman Z-score | −2.20 | −1.00 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 7.1% | 69.7% |
| Held by insiders | 0.18% | 71.7% |
| Short interest, % of float | – | 65.3% |
Go deeper
- MREO stock overview
- MREO income statement
- MREO valuation and score
- SPRB stock overview
- SPRB income statement
- SPRB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.